This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content
HALIFAX, Nova Scotia, Sept. 11, 2026 (GLOBE NEWSWIRE) — Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF), an oncology company developing a therapy to increase the limited efficacy of immunotherapy drugs, today announced that David Regan, CEO, will present live at the OTC Markets’ Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 17th, 2026.
Sign In or Create an Account
or View more offersArticle content
DATE: September 17th
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
TIME: 11:00 am EDT
Article content
Article content
Schedule 1×1 meetings here.
Article content
The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
Mr. Regan will be presenting on Sona’s promising clinical stage, solid cancer treatment, Targeted Hyperthermia Therapy, and how it may enable greater efficacy of some of today’s blockbuster drugs and thereby return significant value to investors.
Article contentArticle content
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Article content
Learn more about the event at www.virtualinvestorconferences.com.
Article content
Recent Company Highlights
Article content
- Sona’s Targeted Hyperthermia Therapy (“THT”) caused an immune system response in 8/10 biopsied tumors, with 6/10 no longer showing signs of cancer, in late stage melanoma patients who had failed on standard immunotherapy drugs.
- Gearing up for a study to assess the further benefits and safety of THT when combined with immunotherapy drugs in patients that previously failed on them.
- THT, which used inert gold nanorods to prime tumors, has shown excellent safety.
- Clinical strategy is supported by significant pre-clinical research published in peer-reviewed scientific journals and an experienced board and management team.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
About Sona Nanotech Inc.
Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, that uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona’s gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion, an approach aligned with the melanoma research community’s active focus on converting immunogenically ‘cold’ tumors, which resist immunotherapy, into ‘hot’ tumors that the immune system can recognize and attack, thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.
Article content
Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech’s gold nanorod particles are cetyltrimethylammonium (“CTAB”) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.